Cipla Limited (CIPLA.NS)
Makes generic medicines and vaccines sold across India and globally
1,474.30+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-1.9%
The outlook
Cipla sits above both its 50- and 200-day moving averages, with analyst consensus leaning toward Buy across broad coverage. The stock trades midway through its 52-week range, and the average analyst target sits roughly 3% above the current price. The overall lean is bullish based on current technicals and sentiment, though the trailing P/E of 35.3 reflects a premium valuation.
What’s behind the score
Analyst consensusBuy — 2.2 avg of 37 analysts
Price trendAbove its 50- & 200-day averages
52-week range61% of the way from its 52-week low to high
Price targetAvg target +3% vs current price
Analyst price target
~12-month · 37 analysts1,512.86average target+2.6% vs now
Now 1,474.30
Low 1,170.00High 1,768.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.19T
52-wk high
1,673.00
52-wk low
1,165.70
50-day avg
1,414.65
200-day avg
1,397.89
Trailing P/E
35.3